Chemotherapy (cisplatin) converts resting platelet into a pyroptotic state. Cisplatin triggers activation of caspase-3. Active caspase-3 cleaves full-length gasdermin E (GSDME) to generate GSDME–N-terminal and GSDME–C-terminal fragments. GSDME–N-terminal protein is recruited to the platelet lipid ra... More about this image found in Chemotherapy (cisplatin) converts resting platelet into a pyroptotic state....

Selected patient characteristics and transplant outcomes. (A) Number of previous therapies. (B) Number of HLH-2004 criteria fulfilled at the time of conditioning. (C) IFS. (D) Probability of second HSCT. ∗∗∗∗ P < .0001; ∗∗ P < .01; ∗ P < .05. Ema, emapalumab. See Figures 1, 3, and 4 in t... More about this image found in Selected patient characteristics and transplant outcomes. (A) Number of pre...

Determinants of primary resistance to BCMA bispecifics in multiple myeloma. High levels of sBCMA, low BCMA surface abundance, unfavorable E:T ratios, suboptimal dosing, and baseline T-cell exhaustion collectively mediate primary refractoriness to BCMA×CD3 antibodies but may be unleashed by therapeut... More about this image found in Determinants of primary resistance to BCMA bispecifics in multiple myeloma....

Hematological event-free survival (EFS) of patients with AL amyloidosis treated with frontline Dara-VCD or Dara-VD. Kaplan-Meier survival curves according to t(11;14) status (A) and 1q gain status (B). See Figure 3A-B in the article by Chakraborty et al that begins on page 2613. More about this image found in Hematological event-free survival (EFS) of patients with AL amyloidosis tre...

Figure 1. Proposed hypothetical pathway for clinical high risk (IPI 3-5) patients with DLBCL in future. An ideal workup should include molecular subtyping, functional imaging with radiomic risk assessment, and ctDNA measurements at the baseline and during treatment. Therapies should be adjusted ... More about this image found in Proposed hypothetical pathway for clinical high risk (IPI 3-5) patients wit...

Figure 2. Relationship between COO and probabilistic genetic subtypes as proposed by Schmitz et al, 24 Chapuy et al, 25 Lacy et al 27 (adapted from Wright et al 26 and de Leval et al 50 ). Major genetic aberrations and prognosis are also shown. The width of the arro... More about this image found in Relationship between COO and probabilistic genetic subtypes as proposed by ...

Figure 1. HLH was more refractory and more active at the time of HSCT in patients receiving emapalumab. (A) The number of salvage therapies used before HSCT, including emapalumab as a salvage agent. Use of salvage therapy was significantly higher in the emapalumab cohort ( P  < .0001). A pers... More about this image found in HLH was more refractory and more active at the time of HSCT in patients rec...

Figure 2. Pre-HSCT emapalumab is associated with higher donor chimerism. (A) Cumulative incidence of mixed chimerism (donor chimerism <95% on 2 consecutive occasions) and severe mixed chimerism (donor chimerism <25%). (B) Minimum donor chimerism obtained within 1 year after HSCT and most r... More about this image found in Pre-HSCT emapalumab is associated with higher donor chimerism. (A) Cumulat...